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Abstract
Background: Cytochrome P450 (CYP) enzymes have the potential to affect colorectal cancer
(CRC) risk by determining the genotoxic impact of exogenous carcinogens and levels of sex
hormones.
Methods: To investigate if common variants of CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1,
CYP17A1 and CYP19A1 influence CRC risk we genotyped 2,575 CRC cases and 2,707 controls for
20 single nucleotide polymorphisms (SNPs) that have not previously been shown to have functional
consequence within these genes.
Results: There was a suggestion of increased risk, albeit insignificant after correction for multiple
testing, of CRC for individuals homozygous for CYP1B1 rs162558 and heterozygous for CYP1A2
rs2069522 (odds ratio [OR] = 1.36, 95% confidence interval [CI]: 1.03–1.80 and OR = 1.34, 95%
CI: 1.00–1.79 respectively).
Conclusion: This study provides some support for polymorphic variation in CYP1A2 and CYP1B1
playing a role in CRC susceptibility.
Background
Recent studies have provided strong evidence that expo-
sure to carcinogens, such as polycyclic aromatic hydrocar-
bons, heterocyclic amines and others in the diet,
influences the risk of developing colorectal cancer (CRC)
[1-3]. In addition to diet, cigarette smoking is another
source of carcinogenic exposure relevant to the large
bowel, and increased risk of CRC associated with smoking
has been documented in several studies (reviewed in [4]).
The genotoxic impact of carcinogen exposure is heavily
influenced by a complex array of metabolic pathways,
which includes the cytochrome P450 (CYP) enzyme sys-
tem. The CYP enzymes also participate in the metabolism
of a number of endogenous compounds, such as sex hor-
mones and fatty acids, which are increasingly recognized
to be relevant to CRC development [5]. Because wide
inter-individual variations in activity of many of the CYP
enzymes have been related to the existence of genetic pol-
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ymorphisms, there is an opportunity to look for inherited
metabolic susceptibilities to CRC.
In the present study, we have investigated the relationship
between single nucleotide polymorphisms (SNP) in
CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1
and CYP19A1 and CRC risk in a large study of 2,575 cases
and 2,707 controls. Our rationale for analysing SNPs
mapping to these CYP genes is that CYP3A4 and CYP3A5
are highly expressed in colonic tissue (reviewed in [6])
and variants of CYP1A2 and CYP1B1 have previously been
associated with CRC risk [7]. Additionally, CYP11A1,
CYP17A1  and  CYP19A1, which encode sex hormone
metabolising CYP enzymes, have been linked to risk of
other types of cancer [8,9] and hence represent credible
candidates as CRC predisposition genes.
Methods
Patients and control subjects
Patients with histologically confirmed adenocarcinomas,
ascertained through an ongoing initiative at the Institute
of Cancer Research/Royal Marsden Hospital NHS Trust
(RMHNHST) (1,474 males, 1,101 females; mean age at
diagnosis 59 years; SD ± 10.1) were included in the study.
Healthy individuals were recruited at centers throughout
the UK as part of the National Cancer Research Network
Trial (1999–2002), the Royal Marsden Hospital Trust/
Institute of Cancer Research Family History and DNA Reg-
istry (1999–2004), or the National Study of Colorectal
Cancer Genetics Trial (2004), all established within the
United Kingdom. Controls (836 males, 1,871 females;
mean age 59 years; SD ± 10.9) were the spouses or unre-
lated friends of patients with malignancies. None of the
controls had a personal history of malignancy at time of
ascertainment. All patients and controls were British Cau-
casians, and there were no obvious differences in the
demography of the two groups in terms of place of resi-
dence within the UK. Blood samples were obtained with
informed consent and ethical review board approval in
accordance with the tenets of the Declaration of Helsinki.
DNA was extracted from samples using conventional
methodologies and quantified using PicoGreen (Invitro-
gen).
SNP genotyping
Genotyping of samples was performed using customized
Illumina (San Diego, CA) Sentrix Bead Arrays according to
the manufacturer's protocols. Annotated flanking
sequence information for each SNP was derived from the
University of California Santa Cruz (UCSC) Human
Genome Browser (Assembly hg17). SNP selection was in
part restricted to those that are amenable to genotyping
using the array-based platform used. DNA samples with
GenCall scores < 0.25 at any locus were considered "no
calls." It has been proposed that alleles linked to complex
disease are likely to reflect modest changes in gene activ-
ity, therefore non-coding SNPs are as likely as coding
SNPs to be associated with complex disease risk [10].
Hence our analysis was largely based on the genotyping
non-coding polymorphisms in introns and within 2 kb of
the mRNA of CYP1A2, CYP1B1, CYP3A4, CYP3A5,
CYP11A1, CYP17A1 and CYP19A1. We did however make
use of genotypes generated from a genome-wide associa-
tion study of coding SNPs we have recently performed
(two SNPs in CYP1B1 and one in CYP3A4 and CYP3A5A)
to assist in haplotype construction. Table 1 provides
details of all 20 SNPs analysed in this current report.
Statistical methods
The relationships between homozygote and heterozygote
carrier status and risk of CRC and between number of
putative risk alleles carried and risk of CRC were assessed
by means of odds ratios (ORs) with 95% confidence inter-
vals (CIs), calculated using logistic regression (adjusting
for age and sex). Where it was not possible to calculate
ORs and their CIs by asymptotic methods, an exact
approach was implemented. A likelihood ratio test was
performed to evaluate the impact of each SNP on case-
control status. To test for population stratification, the dis-
tribution of genotypes in controls was tested for depar-
tures from Hardy-Weinberg equilibrium (HWE). To
investigate epistatic interactions, each pair of SNPs was
evaluated by fitting a saturated logistic regression model
and the log likelihood ratio statistic for comparison with
the main effects model computed. To assess the level of
linkage disequilibrium (LD) between SNPs, we calculated
the pair-wise LD measure D' between consecutive pairs of
markers in the genes CYP1B1, CYP3A4, and CYP3A5 using
the expectation-maximization algorithm to estimate two-
locus haplotype frequencies. The program PHASE [11,12]
which implements a Markov chain Monte Carlo method
was used to generate haplotypes. Haplotype frequencies
in cases and controls were compared by the chi-squared
statistic. We report p-values both before and after adjust-
ment for multiple testing, which was carried out by means
of the Bonferroni correction. All computations were
undertaken using the statistical software packages Stata
(Stata Corp, TX, USA) or LogXact (Cytel Inc., Cambridge,
MA, USA).
Results
Genotypes were obtained for 2,561 of the 2,575 cases
(99.5%) and 2,695 of the 2,707 controls (99.6%). SNP
call rates per sample for each of the 5,256 DNA samples
were > 99.8% in cases and > 99.5% in controls. CYP gen-
otypes and allele frequencies in CRC cases and controls
are detailed in Table 2. Genotypic frequencies of SNPs in
controls were similar to those previously documented in
Caucasians and none were found to violate HWE in con-
trols. Table 2 also details the risk associated with each gen-BMC Cancer 2007, 7:123 http://www.biomedcentral.com/1471-2407/7/123
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otype as quantified by the raw OR and the OR adjusted for
age and gender, and their associated 95% CIs. Two SNPs
showed some evidence of an association with CRC risk:
rs162558, which maps 5' to CYP1B1, and rs2069522,
which maps 5' to CYP1A2. Homozygotes for rs162558 in
CYP1B1 and heterozygotes for rs2069522 in CYP1A2 were
associated with a mildly increased risk of CRC (OR = 1.36,
95% CI: 1.03–1.80 and OR = 1.34, 95% CI: 1.00–1.79
respectively), although neither of these findings were sig-
nificant after correction for multiple testing (adjusted p =
1.0). In the case of rs162558 in CYP1B1, heterozygotes
showed no evidence of increased risk. The logistic regres-
sion model based on alleles did not yield any further sig-
nificant associations.
Data on site of tumour and Duke's stage of tumour were
available for 2,544 and 587 cases respectively. Of the
patients for whom site of tumour was known,1,585 had
colon cancer and 959 had rectal tumours. Of the patients
for whom data regarding Duke's stage were available, 52
were stage A, 227 were stage B, 305 were stage C and 3
were stage D. Stratification of the analysis by each of these
categories did not significantly affect findings.
Estimation of haplotypes in the genes with multiple SNPs
resulted in 5, 4 and 3 common haplotypes (i.e. > 1%) for
CYP1B1, CYP3A4 and  CYP3A5  respectively. There was
strong LD between the five common SNPs in CYP1B1 (D'
> 0.97 for each pair of SNPs), the four common SNPs in
CYP3A4 (D' > 0.95 for each pair of SNPs) and the three
SNPs in CYP3A5 (D' > 0.84 for each pair of SNPs). When
haplotype frequencies were compared in patients and
controls no increased evidence of a relationship with CRC
was apparent (Table 3). The joint effects of the polymor-
phisms on the risk of CRC were evaluated. Twelve pairs of
the SNPs displayed nominal evidence of interaction at the
Table 1: CYP gene polymorphisms analysed
Gene SNP Details Chr Coordinate1 Allele A2B2 Top strand
CYP1A2 rs2069522 within 2kb 5' of mRNA 15 72826286 A G CAGATGGATGGGGAATCCAATAGAG [A/
G]AACAGAGCATGTTTGAAGGCCATGA
CYP1B1 rs1800440 coding N453S 2 38209790 A G TTCTTGGACAAGGAHGGCCTCATCA [A/
G]CAAGGACCTGACCAGCAGAGTGATG
rs1056836 coding L432V 2 38209854 C G AAGTTCTCCGGGTTAGGCCACTTCA [C/
G]TGGGTCATGATTCACAGACCACTGG
rs2617266 intronic 2 38214195 A G GGCTGGTGCCCATGCTGGGGACAGA [A/
G]AGGAGAAGGCGTGACACTCAGGGGT
rs2567206 within 2kb 5' of mRNA 2 38215182 A G CGCTTCATCACAGCCACCTCCAATC [A/
G]AGGCCGCACGGTGTCCCCAGAACCA
rs162558 within 2kb 5' of mRNA 2 38215730 A G ACTTCAACCCGATAAAGTTCGCCGG [A/
G]GCGCGGAGATTCGCCTCCTCCTGCC
rs49785885 within 2kb 5' of mRNA 2 38216383 C G TGAGCTCCACTCGCGCTGCGAATCT [C/
G]GTGCTATTATTGACCTGTTTACAGA
CYP3A4 rs4986910 coding M445T 7 99003175 A G TTTCATGTTCATGAGAGCAAACCTC [A/
G]TGCCAATGCAGTTTCTGGGTCCACT
rs2242480 intronic 7 99006117 A G TTTTACCCAATAAGGTGAGTGGATG [A/
G]TACATGGAGAAGGAGGGAGGAGGTG
rs2687116 intronic 7 99010594 A C AATAAAGCAGTTATTTTTAAGAGAG [A/
C]AAGATAAATAAAAGGAAATAGTAGT
rs4986907 coding R162Q 7 99012078 A G GATGTGTTGGTGAGAAATCTGAGGC [A/
G]GGAAGCAGAGACAGGCAAGCCTGTC
rs12721636 5' UTR 7 99026417 A C GGAAAGCTCCATGCACATAGCCCAG [A/
C]AAAGAGCAACACAGAGCTGAAAGGA
rs2740574 within 2kb 5' of mRNA 7 99026747 A G GAGGACAGCCATAGAGACAAGGGCA [A/
G]GAGAGAGGCGATTTAATAGATTTTA
rs11773597 within 2kb 5' of mRNA 7 99027102 C G CTGTCATGGCTCTGGTCCCTACCAG [C/
G]GTGCTGTACACACAGTGGGCAACTA
CYP3A5 rs15524 3' UTR 7 99083850 A G AGCTTTCTTGAAGACCAAAGTAGAA [A/
G]TCCTTAGAATAACTCATTCTCCACT
ss49785886 coding T398N 7 98894887 A C AAAGGGTCAATGGTGGTGATTCCAA [A/
C]TTATGCTCTTCACCATGACCCAAAG
rs776746 intronic 7 98915190 A G CTTTAAAGAGCTCTTTTGTCTTTCA [A/
G]TATCTCTTCCCTGTTTGGACCACAT
CYP11A1 rs2073475 within 2kb 5' of mRNA 15 72448947 A G TGCCCCACAACACTGGGGGAGGTGC [A/
G]GAGGCCTGAACGGAAGTTGGGGTGG
CYP17A1 rs743572 5' UTR 10 104587142 A G GGTGCCGGCAGGCAAGATAGACAGC [A/
G]GTGGAGTAGAAGAGCTGTGGCAACT
CYP19A1 rs10046 intronic 15 49290278 A G CTACTGATGAGAAATGCTCCAGAGT [A/
G]GGTACTGACCAGCCTTCTCTAGTGT
1Human genome build 35, 2Top strand allele, encoded according to the convention adopted by Illumina, Inc. for strand specific genotype annotation in the absence of a reference 
genomeBMC Cancer 2007, 7:123 http://www.biomedcentral.com/1471-2407/7/123
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Table 2: CYP genotype frequencies in colorectal cancer cases and controls
Gene SNP MAF (cases/controls) Genotype Cases Controls Raw OR (95% CI) Adjusted OR (95% CI) P2
CYP1A2 rs2069522 0.022 AA 2444 2597 1.00 (ref) 1.00 (ref) 0.05
0.017 AB 115 94 1.30 (0.98–1.72) 1.34 (1.00–1.79)
BB 0 0 -- --
CYP1B1 rs18004401 0.178 AA 1734 1790 1.00 (ref) 1.00 (ref) 0.15
0.182 AB 739 828 0.92 (0.82–1.04) 0.90 (0.79,1.01)
BB 86 76 1.17 (0.85–1.60) 1.13 (0.81,1.57)
rs10568361 0.452 AA 519 538 1.00 (0.86–1.17) 1.01 (0.86,1.19) 0.91
0.453 AB 1277 1365 0.97 (0.86–1.10) 0.98 (0.86,1.12)
BB 763 792 1.00 (ref) 1.00 (ref)
rs2617266 0.279 AA 203 197 1.11 (0.90–1.36) 1.06 (0.85–1.33) 0.69
0.271 AB 1022 1062 1.03 (0.92–1.16) 1.05 (0.93–1.18)
BB 1333 1430 1.00 (ref) 1.00 (ref)
rs2567206 0.280 AA 205 199 1.11 (0.90–1.36) 1.06 (0.85–1.33) 0.71
0.271 AB 1019 1062 1.03 (0.92–1.15) 1.05 (0.93–1.18)
BB 1332 1429 1.00 (ref) 1.00 (ref)
rs162558 0.217 AA 1582 1668 1.00 (ref) 1.00 (ref) 0.10
0.210 AB 847 918 0.97 (0.87–1.09) 1.02 (0.90–1.15)
BB 132 108 1.29 (0.99–1.68) 1.36 (1.03–1.80)
ss49785885 0 AA 2561 2691 1.00 (ref) 1.00 (ref) 0.50
0.0004 AB 0 2 0.44 (0–5.60) 0.44 (0–5.60)
BB 0 0 -- --
CYP3A4 rs49869101 0.007 AA 2522 2646 1.00 (ref) 1.00 (ref) 0.56
0.007 AB 38 40 1.00 (0.64–1.56) 1.15 (0.72,1.86)
BB 0 0 -- --
rs2242480 0.089 AA 24 26 0.95 (0.55–1.67) 0.94 (0.53–1.67) 0.36
0.097 AB 410 471 0.90 (0.78–1.04) 0.89 (0.77–1.04)
BB 2127 2198 1.00 (ref) 1.00 (ref)
rs2687116 0.035 AA 2385 2505 1.00 (ref) 1.00 (ref) 0.98
0.036 AB 173 187 0.97 (0.78–1.20) 0.98 (0.78–1.22)
BB 3 3 1.05 (0.21–5.21) 1.00 (0.19–5.26)
rs49869071 0.0006 AA 0 0 -- -- 0.28
0.0002 AB 3 1 3.16 (0.33–30.37) 3.32 (0.32–34.09)
BB 2554 2688 1.00 (ref) 1.00 (ref)
rs12721636 0.0008 AA 0 0 -- -- 0.19
0.0004 AB 4 2 2.11 (0.39–11.51) 2.10 (0.30–23.29)
BB 2556 2691 1.00 (ref) 1.00 (ref)
rs2740574 0.034 AA 2389 2508 1.00 (ref) 1.00 (ref) 0.94
0.035 AB 170 181 0.99 (0.79–1.22) 0.99 (0.78–1.24)
BB 2 3 0.70 (0.12–4.19) 0.73 (0.12–4.66)
rs11773597 0.066 AA 12 13 0.97 (0.44–2.13) 1.08 (0.48–2.43) 0.91
0.067 AB 312 335 0.98 (0.83–1.15) 0.97 (0.81–1.15)
BB 2237 2347 1.00 (ref) 1.00 (ref)
CYP3A5 rs15524 0.076 AA 2186 2261 1.00 (ref) 1.00 (ref) 0.24
0.085 AB 360 408 0.91 (0.78–1.06) 0.92 (0.79–1.08)
BB 15 24 0.65 (0.34–1.24) 0.62 (0.31–1.21)
ss497858861 0.004 AA 1 0 1.05 (0.03-∞) 1.05 (0.03-∞)0 . 0 6
0.007 AB 20 36 0.58 (0.34–1.01) 0.57 (0.32–1.02)
BB 2539 2655 1.00 (ref) 1.00 (ref)
rs776746 0.067 AA 12 16 0.78 (0.37–1.65) 0.75 (0.35–1.63) 0.56
0.073 AB 320 363 0.92 (0.78–1.08) 0.93 (0.79–1.10)
BB 2225 2312 1.00 (ref) 1.00 (ref)
CYP11A1 rs2073475 0.155 AA 64 62 1.11 (0.77–1.58) 1.09 (0.75–1.58) 0.43
0.146 AB 667 661 1.08 (0.95–1.22) 1.09 (0.95–1.24)
BB 1829 1958 1.00 (ref) 1.00 (ref)
CYP17A1 rs743572 0.379 AA 995 1045 1.00 (ref) 1.00 (ref) 0.86
0.383 AB 1192 1234 1.01 (0.90–1.14) 1.00 (0.88–1.13)
BB 374 416 0.94 (0.80–1.11) 0.96 (0.80–1.14)
CYP19A1 rs10046 0.472 AA 714 755 1.00 (ref) 1.00 (ref) 0.37
0.467 AB 1272 1364 0.99 (0.87–1.12) 1.00 (0.88–1.15)
BB 572 575 1.05 (0.90–1.23) 1.11 (0.94–1.30)
MA, minor allele; OR, odds ratio; CI, confidence interval; p, likelihood ratio test p-value; A, B, strand specific allele designations defined in Table 1; 1Hum Mol Genet. 2006 
Nov 1;15(21):3263-71. 2unadjusted p-values, adjusted p = 1.0 (not shown)BMC Cancer 2007, 7:123 http://www.biomedcentral.com/1471-2407/7/123
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5% level, but none were significant after applying a Bon-
ferroni correction for the 105 likelihood ratio tests under-
taken.
Discussion
Two of the variants we evaluated, CYP1A2 rs2069522 and
CYP1B1 rs162558, showed mild evidence of an impact on
CRC risk. For CYP1B1 rs162558, homozygosity was asso-
ciated with increased CRC risk, and for CYP1A2
rs2069522 heterozygosity was associated with risk,
although these associations were not significant after cor-
rection for multiple testing. The Bonferroni correction is
based on the assumption that tests are independent. This
is a conservative adjustment for these data due to the high
levels of LD in CYP1B1, CYP3A4 and CYP3A5. However,
the smallest observed unadjusted p-value of 0.05 would
not be significant after correction for multiple testing even
if a less conservative adjustment (such as adjusting for the
~7 independent tests once LD is taken into account) were
used. Conflicting results from other studies have found
these genes to be either associated or not associated with
CRC risk [7,13]. Discrepancies between these previous
studies may be due to small sample sizes, confounding
interactions with environmental or genetic risk factors,
and the choice of SNPs to be genotyped. We have tested
2575 cases and 2707 controls, over 5-fold more than any
previous study of CRC involving these genes, and hence
had far more power to detect moderate increases in risk.
We acknowledge that the choice of particular SNPs and/or
interactions with other risk factors could moderate the
observed results in any association study. Previous studies
have implicated polymorphisms in the cytochrome P450
genes CYP1A1, CYP2A6, CYP2C9, and CYP2C19 in risk of
CRC (reviewed in [14]). However the small sample sizes
of many early association studies may have led to mis-
leading results. While the precise nature of the role of the
CYP genes in CRC risk is not yet clear, our findings expand
the body of knowledge about these genes, and we hope
they will contribute to the development of further
research in this area.
As the genotypic frequencies of SNPs in our controls were
similar to those previously documented in Caucasians
and none were found to violate Hardy-Weinberg equilib-
rium there is no evidence that cryptic relatedness or pop-
ulation stratification impacted on study findings.
Although we do not have participant rate data it seems
unlikely that any selection from this would bias study
findings (i.e. specific genotype more likely to have been
ascertained).
SNP rs2069522 is located -2847 bp relative to CYP1A2,
within a putative region of bi-directional suppressive tran-
scriptional control (position -1329 to -4412) for both
CYP1A1 and CYP1A2 genes [15], hence it is possible that
this sequence change may influence transcription of
CYP1A1 and CYP1A2 proteins. Previously, SNPs in both
CYP1A1 and CYP1A2 have been associated with colorectal
adenomas and carcinomas [7,16], therefore the observa-
tion of some relationship between CYP1A2  rs2069522
and risk in our study is not without precedent. Moreover,
CYP1A2 is critical for the metabolic activation of dietary
heterocyclic aromatic amines (HCA) which are mutagenic
and have been implicated in the development of CRC [17-
23].
SNP rs162558 is located -1548 bp relative to CYP1B1.
CYP1B1  activates several human procarcinogens by an
aryl hydrocarbon receptor-aryl hydrocarbon receptor
nuclear translocator pathway [24,25]. CYP1B1 is overex-
pressed in colorectal adenocarcinomas relative to normal
colon tissue [26], and a variant with increased activity
towards several substrates including sex hormones has
been associated with increased risk of CRC [7]. Our data
Table 3: CYP haplotype frequencies in colorectal cancer cases and control
Gene Haplotype1 % frequency (standard error) p
Controls Cases
CYP1B1 ABAAAA 26.85 (0.024) 27.7 (0.022) 0.49
AABBAA 24.11 (0.038) 23.6 (0.037) 0.68
AABBBA 20.91 (0.033) 21.5 (0.033) 0.63
BBBBAA 18.01 (0.031) 17.6 (0.029) 0.73
ABBBAA 9.58 (0.035) 8.98 (0.040) 0.46
CYP3A4 ABABBAB 82.64 (0.043) 83.59 (0.026) 0.36
ABABBAA 6.70 (0.0071) 6.55 (0.016) 0.83
AAABBAB 6.30 (0.043) 5.54 (0.028) 0.24
AABBBBB 3.35 (0.0079) 3.32 (0.0086) 0.94
CYP3A5 ABB 90.83 (0.0056) 91.90 (0.0033) 0.17
BBA 7.32 (0.0093) 6.66 (0.0027) 0.72
BBB 1.14 (0.0095) 0.96 (0.0027) 0.24
1The order of genotypes is the order of SNPs as listed in Table 1, haplotypes with frequency less than 1% not shown.BMC Cancer 2007, 7:123 http://www.biomedcentral.com/1471-2407/7/123
Page 6 of 7
(page number not for citation purposes)
support the evidence that genetic variants in CYP1B1 may
be associated with CRC risk.
CYP19A1 rs10046 has previously been reported to influ-
ence levels of estradiol [8] and possibility impact on
breast cancer risk. While estrogens undoubtedly affect
CRC risk, in our study we found no evidence that varia-
tion in CYP19A1 defined by rs10046 had an impact on
CRC risk.
Our study is large compared to contemporaneous studies,
and although for the majority of SNPs assayed our analy-
sis has 80% power to detect a relative risk of 1.5, inevita-
bly we cannot entirely exclude a small effect in risk of CRC
associated with the variants analysed. Moreover, as there
is increasing evidence of a gene-environment effect with
respect to CRC risk some of the polymorphisms may
mediate CRC risk in the context of specific dietary risk fac-
tors. The primary aim of our study design was to acquire
enough samples to achieve statistically significant results
for the identification of common, low penetrance alleles
in CRC. The addition of gene-environment interaction to
our aims would require a vastly larger number of samples
in order achieve significance. We hope that as technologi-
cal advances enable studies of this nature to include larger
numbers of patient samples, reliable information regard-
ing carcinogen exposure and diet will be informative, but
the collection and analysis of environmental factors was
unfortunately not possible on the scale of our study.
Conclusion
This study provides some support for polymorphic varia-
tion in CYP1A2 and CYP1B1 playing a role in CRC suscep-
tibility.
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